Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Valerie Campello-Iddison"'
Autor:
Sinisa Savic, Amparo Lopez Bernus, Rachel A Bender Ignacio, Valerie Campello-Iddison, MeiLan K. Han, Katrin Milger-Kneidinger, Weihua Cao, Ben Parker, Barbara Knorr, Peter Langmuir, Amesika N. Nyaku, Victoria T Potter
Publikováno v:
Clinical Cancer Research. 26:PO-002
Background: Severe COVID-19 can result in pneumonia, with many patients (pts) requiring hospitalization and oxygen support. Severe COVID-19 may also be complicated by acute respiratory distress syndrome, sepsis and septic shock, and/or multiorgan fai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3007e4ff408721fbf9fdbda3bc63161a
https://doi.org/10.1158/1557-3265.covid-19-po-002
https://doi.org/10.1158/1557-3265.covid-19-po-002
Autor:
Maria Zingariello, Anna Rita Migliaccio, Valerie Campello-Iddison, C. Wilke, Shalini Chaturvedi, Paola Verachi, Fabrizio Martelli
Publikováno v:
Blood. 136:26-27
Myelofibrosis (MF), the end stage of Philadelphia-negative Myeloproliferative Neoplasms, is still an unmet clinical need. Treatment with the JAK1/2 inhibitor ruxolitinib ameliorates symptoms and improves overall survival but it is unclear whether it
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1750c137792aba03e475aefe68119014
https://doi.org/10.1182/blood-2020-133896
https://doi.org/10.1182/blood-2020-133896
Autor:
Adolfo Fuentes, Joan Maier, Anne Ruault, Ythier Deniau, Moez Ben Ali, Valerie Campello-Iddison, Laura Cuenot
Publikováno v:
Journal of Clinical Oncology. 36:TPS7079-TPS7079
TPS7079Background: FLT3 mutations, found in ≈30% of pts with AML, are associated with a poor prognosis. Midostaurin is a multikinase inhibitor that targets FLT3 and other kinases involved in AML pa...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ca9b209f41fff13fd63e8cf1954f1fc0
https://doi.org/10.1200/jco.2018.36.15_suppl.tps7079
https://doi.org/10.1200/jco.2018.36.15_suppl.tps7079
Autor:
Stefan Klein, Xiaoshu Feng, Markus Munder, Mohamed Elemary, Katja Weisel, Heinz Gisslinger, Sameer Yaser, Andreas Guenther, Fredrik Schjesvold, Valerie Campello-Iddison, Hareth Nahi, Mathias Haenel, Richard Greil, Denise Wolleschak, Lars-Olof Mügge, Alexander Kiani, Holger Hebart, Christian Junghanss, Hermann Einsele, Ythier Deniau, Martin Goerner, Jan Dürig, Daniel Lechner, Eberhard Gunsilius
Publikováno v:
Blood. 128:5692-5692
Introduction: Panobinostat (PAN) is a potent pan-deacetylase inhibitor that targets multiple myeloma (MM) cells via its epigenetic effects as well as its effect on the aggresome. In the PANORAMA 1 phase 3 trial, the combination of PAN, bortezomib (BT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8cc0ea161f6319d1eee5ca0b72143502
https://doi.org/10.1182/blood.v128.22.5692.5692
https://doi.org/10.1182/blood.v128.22.5692.5692
Phase 1 study of VX15/2503, a humanized IgG4 anti-SEMA4D antibody, in advanced cancer patients (pts)
Autor:
Cynthia Eddington, Ramesh K. Ramanathan, Danielle Mutz, Anthony W. Tolcher, Terrence L. Fisher, John E. Leonard, Amita Patnaik, Valerie Campello-Iddison, Glen J. Weiss, Lisa Blaydorn, Drew W. Rasco
Publikováno v:
Journal of Clinical Oncology. 32:3052-3052
3052^ Background: Semaphorin 4D (SEMA4D) regulates cellular adhesion, motility and activation of cells of the nervous, vascular and immune systems; it also promotes tumor progression and metastasis...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a699898af5fbadcfb1ad76a2743079ca
https://doi.org/10.1200/jco.2014.32.15_suppl.3052
https://doi.org/10.1200/jco.2014.32.15_suppl.3052